Pharmacokinetics News and Research

RSS
The term pharmacokinetics is derived from the ancient Greek words “pharmakon” and “kinetikos”, meaning “drug” and “putting in motion” respectively. It is one of the main branches of pharmacology, and refers to the way that the body reacts on and affects a pharmaceutical substance in the body.

Further Reading

ADVENTRX updates ANX-514 candidate for FDA approval

ADVENTRX updates ANX-514 candidate for FDA approval

16 Feb 2011
Raptor reopens enrollment in DR Cysteamine Phase 3 trial to treat patients with nephropathic cystinosis

Raptor reopens enrollment in DR Cysteamine Phase 3 trial to treat patients with nephropathic cystinosis

15 Feb 2011
State court jury rules in favor of Merck in FOSAMAX trial

State court jury rules in favor of Merck in FOSAMAX trial

15 Feb 2011
PROLOR reports positive DSMB review of long-acting human growth hormone clinical trial

PROLOR reports positive DSMB review of long-acting human growth hormone clinical trial

14 Feb 2011
Study finds too low drug concentrations used for treatment of children with TB

Study finds too low drug concentrations used for treatment of children with TB

11 Feb 2011
Promedior initiates Phase 1b clinical study of PRM-151 in patients with IPF

Promedior initiates Phase 1b clinical study of PRM-151 in patients with IPF

11 Feb 2011
Medivir initiates phase 1a clinical trial of TMC649128 for chronic HCV infection

Medivir initiates phase 1a clinical trial of TMC649128 for chronic HCV infection

10 Feb 2011
Targacept initiates TC-6987 Phase 2 study in patients with asthma, Type 2 diabetes

Targacept initiates TC-6987 Phase 2 study in patients with asthma, Type 2 diabetes

9 Feb 2011
R-Tech commences RK-023 Phase I study for treatment of eyelash hypotrichosis

R-Tech commences RK-023 Phase I study for treatment of eyelash hypotrichosis

9 Feb 2011
Gentium completes Defibrotide clinical studies, plans to file for regulatory approval

Gentium completes Defibrotide clinical studies, plans to file for regulatory approval

9 Feb 2011
Transition reports second quarter 2011 net income of $24.28M vs. $6.05M net loss for second quarter 2010

Transition reports second quarter 2011 net income of $24.28M vs. $6.05M net loss for second quarter 2010

8 Feb 2011
Tufts announces public launch of Institute for Biomedical Partnerships, HUB website

Tufts announces public launch of Institute for Biomedical Partnerships, HUB website

8 Feb 2011
Anacor initiates dosing in AN2728 Phase 2b trial for psoriasis

Anacor initiates dosing in AN2728 Phase 2b trial for psoriasis

4 Feb 2011
MicroCHIPS commences first hPTH clinical study in women with osteoporosis

MicroCHIPS commences first hPTH clinical study in women with osteoporosis

4 Feb 2011
Inspiration presents IB1001 PK data for treatment of hemophilia B

Inspiration presents IB1001 PK data for treatment of hemophilia B

3 Feb 2011
Inspiration presents IB1001 PK data at European haemophilia congress

Inspiration presents IB1001 PK data at European haemophilia congress

3 Feb 2011
Aphios enters subcontract with SAIC-Frederick to develop phospholipid nanoencapsulated camptothecin

Aphios enters subcontract with SAIC-Frederick to develop phospholipid nanoencapsulated camptothecin

2 Feb 2011
Antares initiates dosing in VIBEX MTX clinical study for rheumatoid arthritis

Antares initiates dosing in VIBEX MTX clinical study for rheumatoid arthritis

2 Feb 2011
Biogen Idec 2010 total revenues increase 8% to $4.7 billion

Biogen Idec 2010 total revenues increase 8% to $4.7 billion

1 Feb 2011
Maxygen initiates Phase I study to evaluate CTLA4-Ig therapeutic for treatment of rheumatoid arthritis

Maxygen initiates Phase I study to evaluate CTLA4-Ig therapeutic for treatment of rheumatoid arthritis

31 Jan 2011

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback